comparemela.com

Page 7 - Zacks Medical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks investment researchSolid biosciences incAnika therapeuticsZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankSolid biosciencesZacks investmentZacks rankStimate revisionsMedical technology companyOnsensus estimateQuarterly lossPs estimates

Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of 23.68% and 4.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Veru incZacks investment researchZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankZacks investmentZacks rankStimate revisionsMedical technology companyPs estimatesOnsensus estimateQuarterly lossConsensus eps estimateArnings estimate

Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks investment researchSupernus pharmaceuticalsZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankAgile therapeuticsZacks investmentZacks rankStimate revisionsOnsensus estimatePs estimatesConsensus eps estimateQuarterly lossConsensus earnings

Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks investment researchEmergent biosolutionsZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankLifecore biomedicalZacks investmentZacks rankStimate revisionsLifecore biomedicalQuarterly lossOnsensus estimatePs estimatesArnings estimate

ICU Medical (ICUI) Beats Q2 Earnings Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks investment researchIm cannabis corpZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankZacks investmentIcu medicalZacks rankQuarterly earningsStimate revisionsOnsensus estimatePs estimatesArnings surpriseConsensus eps estimate

vimarsana © 2020. All Rights Reserved.